Kodiak Sciences Revenue and Competitors

Location

$1B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Kodiak Sciences's estimated annual revenue is currently $15.7M per year.(i)
  • Kodiak Sciences's estimated revenue per employee is $141,036
  • Kodiak Sciences's total funding is $1B.

Employee Data

  • Kodiak Sciences has 111 Employees.(i)
  • Kodiak Sciences grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

Kodiak is a high-science retinal medicines development company. We are aspiring to build a dominant global retina franchise. We are developing a top pipeline of proprietary best-in-class medicines for the treatment of patients with age-related macular degeneration and diabetic eye disease, two leading causes of blindness. Our science begins with an antibody biopolymer product platform merging the fields of biologics and chemistry based therapies. In our medicines we aim to restore vision, to stop progression of underlying disease, and to require fewer treatments. WORKING AT KODIAK We are passionate about preventing blindness and improving health. We take pride in scientific and operational excellence. The curiosity, creativity, and courage of our team members drives our progress. We highly value this culture and support it every way we can. Kodiak supports a vibrant and active lifestyle. We have a top benefits package. We are within walking distance to California Avenue shops, restaurants and public transportation.

keywords:N/A

$1B

Total Funding

111

Number of Employees

$15.7M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Kodiak Sciences News

2022-04-17 - Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Down ...

Get Kodiak Sciences alerts: In other news, Director Bros. Advisors Lp Baker bought 133,414 shares of the stock in a transaction on Friday...

2022-04-13 - Kodiak Sciences Inc. (NASDAQ:KOD) Receives $45.89 ...

Kodiak Sciences Inc. (NASDAQ:KOD) Receives $45.89 Average Price Target from Brokerages. Posted by admin on Apr 13th, 2022.

2022-04-06 - Analyst Ratings for Kodiak Sciences - Benzinga

Within the last quarter, Kodiak Sciences KOD has observed the following analyst ratings: Bullish, Somewhat Bullish, Indifferent...

2021-09-01 - Kodiak Sciences : Announces New Long-Term Performance Incentive Plan

PALO ALTO, Calif., Sept. 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced new seven-year performance stock option ...

2018-04-26 - Kodiak Sciences Closes $33M Mezzanine Private Financing

Kodiak Sciences Inc., a Palo Alto, CA-based development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, completed a $33m mezzanine private financing of convertible notes. Backers included Perceptive Advisors and ArrowMark Partners ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.5M11116%N/A
#2
$11.3M111-7%N/A
#3
$24.4M11131%N/A
#4
$16.2M11237%N/A
#5
$15M1138%N/A